SIGA TERMINATES MERGER AGREEMENT WITH PHARMATHENE, INC.

SIGA Technologies, Inc. disclosed that it had terminated its Agreement and Plan of Merger with PharmAthene, Inc., pursuant to the terms of that agreement. In reaching its decision, the SIGA Board of Directors considered many factors, including recent positive scientific data and the receipt of approximately $27 million in grants for its smallpox and arenavirus programs over the last several months, which amount includes a grant of $16.5 million from the National Institutes of Health also announced. Genetic Engineering News (http://www.genengnews.com/news/bnitem.aspx?name=6507160)